Adaptimmune Therapeutics Plc

ADAP

NASDAQ. Currency in USD

1.31 +0.01 ( +0.77% )

Real time prices: December 19

Market Cap.
214.62M
Beta (5Y monthly)
2.13
Price/Earnings
-
EPS (TTM)
-1.09
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
165,001
1y Target Est.
5.33
Day's Range
1.25
-
1.32
52 Week's Range
1.01
-
3.31

Historical Summary

Performance
EPS growth
Share Buybacks

About Adaptimmune Therapeutics Plc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.adaptimmune.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
156.86M
Employees
494
Address
60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Latest news

Credit Suisse, Autodesk And Other Big Losers From Wednesday
Credit Suisse, Autodesk And Other Big Losers From Wednesday

U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points....
By Benzinga - 9 weeks ago

5 Penny Stocks To Buy According To Analysts, Targets Up To 353%
5 Penny Stocks To Buy According To Analysts, Targets Up To 353%

Analysts say these are penny stocks to buy. Do you agree? The post 5 Penny...
By PennyStocks - 11 weeks ago

Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022

Upgrades Janney Montgomery Scott upgraded the previous rating for First Bancshares Inc (NASDAQ:FBMS) from Neutral...
By Benzinga - 11 weeks ago

Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique...
By Benzinga - 11 weeks ago

Why Adaptimmune Therapeutics Stock Is Glowing Green Today
Why Adaptimmune Therapeutics Stock Is Glowing Green Today

Positive trial data is powering the biotech's stock higher today.
By The Motley Fool - 11 weeks ago

12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers DBV Technologies (NASDAQ:DBVT) stock increased by 18.7% to $1.9 during Tuesday's after-market session. The...
By Benzinga - 13 weeks ago

Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket

Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
By The Motley Fool - 30 weeks ago